Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design

Increased affinities mainly equal to improved biological efficacy in many cases. By now, display methods including phage library are widely exploited to obtain higher affinity antibodies. Traditional library methods mainly focus on complementary determining region mutagenesis, in which extensive screening of variant combinations as well as large library capacity is required to find higher affinity clones. In this study, based on the modeling 3D complex structure of antigen (HER2)–antibody (MIL5) complex, the key residues of contact surface were predicted and identified to guide the synthetic phage library design. Then, epitope-specific site-directed mutagenesis phage library comprised of MIL5_scFv mutants was constructed, from which a higher affinity single chain antibody (M5scFv_ph) was screened out. Following experimental results showed that the novel antibody M5scFv_ph retained superimposed epitope to the parent antibody MIL5_scFv, and possessed similar tumor growth inhibitory activity in vivo on ovarian carcinoma xenografts.

[1]  M. Hensler,et al.  Stepwise in vitro affinity maturation of Vitaxin, an αvβ3-specific humanized mAb , 1998 .

[2]  I. Kuntz,et al.  Protein docking and complementarity. , 1991, Journal of molecular biology.

[3]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[4]  B. Henderson,et al.  Phage display in the study of infectious diseases , 2006, Trends in Microbiology.

[5]  George Georgiou,et al.  Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Tristan J. Vaughan,et al.  Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library , 1996, Nature Biotechnology.

[7]  Peter Bohlen,et al.  Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity* , 2003, Journal of Biological Chemistry.

[8]  M. Sliwkowski,et al.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.

[9]  H. Hoogenboom,et al.  Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.

[10]  P. T. Jones,et al.  Isolation of high affinity human antibodies directly from large synthetic repertoires. , 1994, The EMBO journal.

[11]  A. Wehnert,et al.  Construction and diversification of yeast cell surface displayed libraries by yeast mating: application to the affinity maturation of Fab antibody fragments. , 2004, Gene.

[12]  Hassan M E Azzazy,et al.  Phage display technology: clinical applications and recent innovations. , 2002, Clinical biochemistry.

[13]  Hennie R. Hoogenboom,et al.  A Large Non-immunized Human Fab Fragment Phage Library That Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies* , 1999, The Journal of Biological Chemistry.

[14]  D. Slamon,et al.  Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. , 2001, Seminars in oncology.

[15]  K. Wittrup,et al.  Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. , 2004, Nucleic acids research.

[16]  H. Hoogenboom.  Overview of antibody phage-display technology and its applications. , 2002, Methods in molecular biology.

[17]  R. Begent,et al.  Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37°C , 2004 .

[18]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Rupprecht,et al.  The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries , 2005, European journal of immunology.

[20]  A. Pini,et al.  Design and Use of a Phage Display Library , 1998, The Journal of Biological Chemistry.

[21]  C. Arteaga.  Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer , 2003, Breast Cancer Research.

[22]  M. Hensler,et al.  Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S E Hufton,et al.  Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  王琰,et al.  Construction of a large single-chain phage antibody library , 2004 .

[25]  C D Maranas,et al.  OptCDR: a general computational method for the design of antibody complementarity determining regions for targeted epitope binding. , 2010, Protein engineering, design & selection : PEDS.

[26]  Y. Kan,et al.  Antibodies to human fetal erythroid cells from a nonimmune phage antibody library , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[28]  S. Connolly,et al.  Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. , 1983, The American journal of cardiology.

[29]  G. Adams,et al.  Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. , 1996, Journal of molecular biology.

[30]  C. Broder,et al.  UvA-DARE ( Digital Academic Repository ) Neutralizing antibodies to the HIV-1 envelope glycoproteins , 2009 .

[31]  César Milstein,et al.  Man-made antibodies , 1991, Nature.

[32]  E. H. Cohen,et al.  Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity , 2005, Nature Biotechnology.

[33]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[34]  A. Plückthun,et al.  Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Mitchell Ho,et al.  In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin* , 2005, Journal of Biological Chemistry.

[36]  I. Kuntz,et al.  Matching chemistry and shape in molecular docking. , 1993, Protein engineering.

[37]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[38]  R. Begent,et al.  Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. , 2004, Protein engineering, design & selection : PEDS.

[39]  A. Plückthun,et al.  Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. , 2000, Journal of molecular biology.

[40]  L. Presta,et al.  Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab , 2006, Cancer Immunology, Immunotherapy.

[41]  Robert Charles Ladner,et al.  Affinity maturation of Fab antibody fragments by fluorescent‐activated cell sorting of yeast‐displayed libraries , 2003, FEBS letters.

[42]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[44]  G. Sakamoto,et al.  New molecule-targeting therapy with Herceptin (Trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody , 2000, Breast cancer.

[45]  E. Liu,et al.  HER2 as a predictor of therapeutic response in breast cancer. , 2000, Breast disease.

[46]  D R Burton,et al.  CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. , 1995, Journal of molecular biology.

[47]  N. Hynes,et al.  The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.

[48]  H. Lorenz.  Technology evaluation: adalimumab, Abbott laboratories. , 2002, Current opinion in molecular therapeutics.